DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05295940

CompletedPhase 1

A Study of LY3841136 in Healthy and Overweight Participants

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3841136 in Healthy and Overweight Participants

Asset

Eloralintide

Subcutaneous · Amylin analog

Listed sites

3

Recruiting sites

—

Enrollment

148

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criterion

•BMI 18.5-32

Primary endpoint

•Treatment-emergent AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05295940
Org study ID18309
Secondary IDJ3R-MC-YDAAEli Lilly and Company

Timeline

Milestones

Study first posted2022-03-25actual
Study start2022-03-30actual
Primary completion2024-01-25actual
Study completion2024-01-25actual
Last update posted2024-04-01actual

Assets

Investigational agents

Eloralintide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
•Have had a stable weight for the last 3 months
•Have a body mass index (BMI) in the range of 18.5 to 32 kilogram per square meter (kg/m²), both inclusive (in Part A) or a BMI in the range of 27 to 40 kg/m², both inclusive (in Part B)

Exclusion criteria

•Are women who are lactating
•Have known allergies to related compounds of LY3841136 or any components of the formulation
•Have a history of significant atopy (severe or multiple allergic manifestations), or clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions
•Have been diagnosed with Type 1 or Type 2 diabetes mellitus
•Have a history of chronic medical conditions involving the heart, liver, or kidneys

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
3
Weight & body composition
1

Weight & body composition

1 endpoint
Secondary/protocol endpoint

Pharmacodynamics (PD): Change From Baseline in Body Weight

Time frame:Predose through week 28

Body weight, absolute change (kg)

change from baseline, improvement

Safety / tolerability / PK

3 endpoints
Primary/protocol endpoint

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Predose up to 14 weeks (Part A) & 28 weeks (Part B)

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3841136

Time frame:Predose through week 14 (Part A) & week 28 (Part B)

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Observed Concentration (Cmax) of LY3841136

Time frame:Predose through week 14 (Part A) & week 28 (Part B)

Cmax

concentration, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.